High impact
Merck and Moderna's Intismeran Phase 3 trial met its primary endpoint, showing the shot prevented melanoma recurrence.
LiveSquawk08/19, 05:47 PM
Related assets
Coming up for MRK
Explore next
Latest MRK news
Jin1010/23, 12:41 AM
Jin1008/21, 09:26 PM
Merck (MRK) stock rose 3.7% intraday, breaking above Wednesday's record high.
Finnhub08/20, 08:06 PM